Key result
Bone marrow TTP deficiency in LDLR-/- mice increased systemic inflammation and mitochondrial ROS but reduced serum VLDL/LDL levels, resulting in no net changes in atherosclerosis.
Why the study?
To test the hypothesis that Tristetraprolin in bone marrow cells regulates atherogenesis by modulating inflammation and lipid metabolism through oxidative stress pathways.
Does bone marrow TTP deficiency alter atherogenesis, inflammation, and lipid metabolism in LDLR-/- mice?
Does bone marrow TTP deficiency alter atherogenesis, inflammation, and lipid metabolism in LDLR-/- mice?
Bone marrow TTP deficiency increases systemic inflammation but paradoxically reduces hepatic VLDL/LDL production, leading to a net neutral effect on atherosclerosis in an LDLR-/- mouse model.
Tristetraprolin (TTP), an mRNA binding and decaying protein, plays a significant role in controlling inflammation by decaying mRNAs encoding inflammatory cytokines such as TNFalpha. We aimed to test a hypothesis that TTP in bone marrow (BM) cells regulates atherogenesis by modulating inflammation and lipid metabolism through the modulation of oxidative stress pathways by TTP target genes. In a BM transplantation study, lethally irradiated atherogenic LDLR−/− mice were reconstituted with BM cells from either wild type (TTP+/+) or TTP knockout (TTP−/−) mice, and fed a Western diet for 12 weeks. We made the following observations: (1) TTP−/− BM recipients display a significantly higher systemic and multi-organ inflammation than TTP+/+ BM recipients; (2) BM TTP deficiency modulates hepatic expression of genes, detected by microarray, involved in lipid metabolism, inflammatory responses, and oxidative stress; (3) TTP−/− BM derived macrophages increase production of mitochondrial reactive oxygen species (mtROS); (4) BM-TTP−/− mice display a significant reduction in serum VLDL/LDL levels, and attenuated hepatic steatosis compared to controls; and (5) Reduction of serum VLDL/LDL levels offsets the increased inflammation, resulting in no changes in atherosclerosis. These findings provide a novel mechanistic insight into the roles of TTP-mediated mRNA decay in bone marrow-derived cells in regulating systemic inflammation, oxidative stress, and liver VLDL/LDL biogenesis.
No takes yet. Share an insight, caveat, or question.
Saaoud et al. (2020) studied Atherogenesis and inflammation. Bone marrow cells from TTP knockout (TTP-/-) mice vs. Bone marrow cells from wild type (TTP+/+) mice was evaluated on Atherosclerosis, systemic inflammation, and serum VLDL/LDL levels. Bone marrow TTP deficiency in LDLR-/- mice increased systemic inflammation and mitochondrial ROS but reduced serum VLDL/LDL levels, resulting in no net changes in atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: